永存原始玻璃体增生症微创玻璃体手术观察  

Research on minimally invasive vitrectomy for persistent hyperplastic primary vitreous

作　　者：高延庆[1] 沈策英 潘俊辉[1] 李乐[1] 王向华[1] 

机构地区：[1]郑州市第二人民医院眼科,郑州450006

出　　处：《医药论坛杂志》2016年第3期34-35,共2页Journal of Medical Forum

摘　　要：目的探讨微创玻璃体切除手术治疗永存原始玻璃体增生症（PHPV）的效果。方法所有病例均采用25G微创玻璃体切除术,伴并发性白内障者,术中行晶状体咬切术。所有患者术前和术中均未行玻璃体腔内注射抗血管内皮生长因子药物。术后抗炎、止血治疗。术后随访6～12个月。随访期间观察患者的视力、眼压、眼前后节和B超。结果所有患者均顺利完成手术,术中未遇到影响手术操作的大量出血。术后所有患者视网膜复位,无视网膜脱离复发、感染、脉络膜脱离等并发症。术后随访,无再次行玻璃体手术患者。结论微创玻璃体切除手术,能有效处理混合型PHPV的严重合并症,降低手术风险,并发症少,提高患者术后视力。Objective To evaluate the efficacy of minimally invasive vitrectomy for persistent hyperplastic primary vitreous（ PHPV）. Methods All cases were with 25 G of minimally invasive vitrectomy and resected lens with complicated cataract. All the patients were not injected anti- VEGF drugs intraoperative and postoperative. Take conventional anti-inflammatory,hemostasis. Follow up 6- 12 months postoperation. To observe the visual acuity,intraocular pressure,anterior segment and fundi,and B uitrasound during the follow- up. Results All the patients underwent surgery successfully and we did not encounter much bleeding intraoperative. All cases retinal reattachment,there were no complications such as infection and choroid detachment and retinal detachment recurrence after surgery. There were not revitreous surgery patients during the follow- up postoperative. Conclusion Minimally invasive vitrectomy could treat PHPV effectively,reduce surgical risk,decrease complications,improve visual acuity.

关 键 词：微创玻璃体切除手术 永存原始玻璃体增生症 并发症 

分 类 号：R776.4[医药卫生—眼科]